Related Experiment Video
Updated: Jun 26, 2026

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
Published on: March 5, 2018
Risk-adapted induction and consolidation therapy in adults with de novo AML aged </= 60 years: results of a
G Heil1, J Krauter, A Raghavachar
1Department of Hematology, Hemostaseology and Oncology, Hannover Medical School, University of Hannover, Carl-Neuberg-Str. 1, 30625 Hannover, Germany. innere5@kkh-luedenscheid.de
Abstract:
We treated 305 de novo acute myeloid leukemia (AML) patients aged =60 years with risk-adapted therapy. Patients with CBF leukemias or normal karyotype and good response to induction I [=5% bone marrow (BM) blasts on day 15] were considered standard risk (SR), all others as high risk (HR). Patients with t(15;17) were excluded. Chemotherapy comprised double induction followed by early consolidation. As late consolidation, SR patients received high-dose cytarabine/daunorubicin (AraC/DNR). SR patients with normal karyotype were allotransplanted from HLA-matched siblings. HR patients were allotransplanted or if no sibling donor was available autotransplanted with peripheral blood progenitor cells (PBSC) harvested after early consolidation. 89% of the SR and 60% of the HR patients achieved CR. The continuous complete remission (CCR) rate at 80 months (median follow-up: 48 months) was 48% for SR and 32% for HR. The CCR rate was 54% for t(8;21), 47% for normal karyotype, and 33% for inv(16) patients. In the HR group, the CCR rate did not differ significantly for patients with bad response to IVA-I, unfavorable karyotype, or both. Forty-five HR patients were autotransplanted (n=20) or allotransplanted (n=25). The probability of CCR was 44% for autotransplantation vs 33% for allotransplantation. In conclusion, our risk-adapted strategy produced encouraging results in SR patients. Early response to therapy is a strong prognostic factor that predicts the probability of CR and long-term outcome.
Related Concept Videos
Treatment Resistant Cancers
Treatment Resistent Cancers
Clinical Trials
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview

